EIGR Eiger BioPharmaceuticals Inc.

10.92
-0.37  -3%
Previous Close 11.29
Open 11.32
Price To Book 5.25
Market Cap 266,835,038
Shares 24,435,443
Volume 159,132
Short Ratio
Av. Daily Volume 284,441

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released October 16, 2018 - endpoints met. Data presented at ENDO March 25, 2019.
Avexitide (Exendin 9-39)
Post-Bariatric Hypoglycemia (PBH)
Phase 2 LIMT data noted 36% curable virologic response at 24 weeks post-treatment - April 11. 2019.
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
Phase 3 enrolment to be completed by the end of 2019.
Lonafarnib - D-LIVR
Chronic hepatitis delta virus (HDV)
Phase 2 trial did not meet endpoints - January 16, 2018.
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2 data released October 16, 2018 did not meet endpoints.
Ubenimex - ULTRA
Secondary lymphedema
Phase 2b negative data released April 2015. Formerly CLDN pre-merger
MYDICAR - CUPID 2 Trial
Ischemic or dilated cardiomyopathy
Phase 2 data to be presented at AASLD November 8-12, 2019.
Pegylated interferon lambda + ritonavir (RTV)-boosted lonafarnib (LNF) - LIFT
Hepatitis delta virus (HDV)
NDA filing due 2019.
Lonafarnib
Hutchinson-Gilford Progeria Syndrome (HGPS)

Latest News

  1. Need To Know: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Insiders Have Been Buying Shares
  2. What Makes Eiger BioPharma (EIGR) a New Buy Stock
  3. Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR)
  4. The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale
  5. Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
  6. Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development
  7. Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
  8. Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer
  9. Eiger BioPharma: 1Q Earnings Snapshot
  10. Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
  11. Eiger to Present at ChinaBio® Partnering Forum 2019
  12. Do Institutions Own Shares In Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)?
  13. Weekly CFO Buys Highlight
  14. Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
  15. Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
  16. Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors
  17. Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
  18. Eiger BioPharmaceuticals to Participate in Conferences in April
  19. Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
  20. Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019